Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Members of the Sackler family will dedicate at least $5.5 billion plus 100% of the debtors’ assets to opioid abatement and victims.
ABVC Biopharma, based in California, has programs in Phase II trials to treat major depressive disorder, adult attention deficit hyperactivity disorder and myelodysplastic syndrome.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
At this time, Civica plans a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pen cartridges. It believes it can have these versions of insulin available by 2024.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy later this year. Tonix wins Orphan Drug designation for Prader-Willi asset.
Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
Shares of NuCana have plunged more than 57% in premarket trading after the company announced its Phase III biliary tract cancer study. See more facts here.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
Healx brings the power of artifical intelligence (AI) to rare disease research with an ultimate focus on improving patient outcomes.